5 Low P/B Stocks With Attractive Value and Strong Growth Potential

A Zacks value screen identified 18 qualifying low-price-to-book stocks, highlighting Banco Macro, Centene, EnerSys, Gibraltar Industries and Kennametal based on below-industry valuation metrics, Zacks Rank #1 or #2, and Value Scores of A or B. Centene has the highest projected 3-5-year EPS growth at 32.4%, followed by Banco Macro at 26.6%, Kennametal at 21.1%, and EnerSys and Gibraltar at 15.0% each. The article is a stock-screening and valuation commentary rather than a company-specific operational update.

Analysis

This is a low-information screen rather than a new fundamental catalyst; the near-term trading effect should be negligible. The key error is treating low P/B as comparable across these businesses: CNC's value rests on normalized medical-cost trends and state-rate adequacy, while ENS, ROCK and KMT need tangible order, pricing and utilization evidence. A valuation rerating requires earnings-estimate revisions or a reduction in perceived cyclicality—not merely continued screen eligibility.

CNC is the most actionable name because a favorable medical-loss-ratio progression can produce both EPS upside and multiple expansion over the next 1-3 quarters; the principal falsifier is renewed pressure in Medicaid acuity, risk adjustment or state reimbursement that forces a guide-down. KMT and ROCK offer more cyclical torque but are effectively plays on industrial production, housing/non-residential activity and customer destocking; absent improving bookings and backlog conversion, their low multiples can remain justified. ENS has a differentiated potential catalyst through data-center and grid-resilience demand, but investors should require evidence that higher-growth reserve-power mix is lifting margins rather than merely revenues.

BMA is not a conventional value factor exposure: its book value and earnings power are dominated by Argentine inflation accounting, FX translation, sovereign-risk appetite and regulatory policy. It can outperform sharply in a credible disinflation/currency-normalization regime, but should be sized as a high-beta country-risk position, not as a bank P/B mean-reversion trade. Contrarian view: the screen's apparent diversification masks a common vulnerability to weakening nominal growth and higher real rates, which would pressure industrial volumes, healthcare enrollment/rates and Argentine asset valuations simultaneously.

Key Decisions for Investors

• Initiate a 3-6 month, modest long CNC position only after confirmation that management reiterates or raises full-year medical-cost and EPS guidance; target 15-20% upside on estimate recovery/multiple normalization, with exit on a material medical-loss-ratio deterioration or state-rate shortfall.
• Use a 6-12 month pair trade: long ENS / short KMT in equal dollar amounts. ENS has greater exposure to structural power-resilience and data-center capex, while KMT is more exposed to broad manufacturing and commodity-sensitive end markets; close if ENS bookings fail to outgrow KMT orders for two reporting periods.
• Keep ROCK on watch rather than buy immediately. Add only if quarterly backlog/order growth turns positive and margins hold despite volume recovery; otherwise low P/B likely reflects residential and building-product cyclicality rather than mispricing.
• Treat BMA as a tactical, small-risk event position only around independently verifiable Argentine policy milestones—reserve accumulation, FX-regime normalization and disinflation. Use a hard risk limit: exit on renewed capital controls, a material peso devaluation without inflation stabilization, or widening sovereign spreads.
• Do not add basket exposure solely on this screen. Re-rank after next earnings using estimate revisions, free-cash-flow conversion, net leverage and return on invested capital; these metrics—not P/B—will determine whether a 6-18 month rerating is investable.